The HSP90 inhibitor KW-2478 depletes the malignancy of BCR/ABL and overcomes the imatinib-resistance caused by BCR/ABL amplification
Abstract Background With the widespread clinical application of tyrosine kinase inhibitors (TKIs), an increasing number of chronic myeloid leukaemia (CML) patients have developed resistance or intolerance to TKIs. BCR/ABL is the oncoprotein of CML. HSP90 is an essential chaperone of BCR/ABL and play...
Salvato in:
| Autori principali: | , , , , , , , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
BMC
2022-05-01
|
| Serie: | Experimental Hematology & Oncology |
| Soggetti: | |
| Accesso online: | https://doi.org/10.1186/s40164-022-00287-w |
| Tags: |
Nessun Tag, puoi essere il primo ad aggiungerne!!
|